What is it? Why is it important?
- Substantial, or
Before a substantial amendment can be implemented it must be approved by EC and if applicable by RA. Exceptions are safety amendments which are required to protect study participants. Still, EC and RA should be informed as quickly as possible.
Changes impacting the collection of study data are generally substantial amendments (e.g. the inclusion of additional study site(s) or data).
Substantial amendments require:
- An initial protocol revision including approval by EC/RA
- Adaptations / expansion of the study database (eCRF)
- Validation, approval and release of the newly adapted database
Examples of amendments that might affect study data collection
- New scientific evidence becomes available that require an adaptation regarding study aim, safety concerns, data collection and statistical study plan
- The collected data is shown to be inadequate to answer the study question. The collection of additional data (variables) becomes necessary (e.g. additional blood samples, medical tests, participant feedback)
- The total number of study participants needs to be increased. In order to gain access and recruit adequate participants the inclusion of additional study site(s) becomes necessary
What do I need to do?
Evaluate the impact of an amendment on the:
- Study database (eCRF), pCRFs, study randomisation processes, existing data, subsequent data analysis and evaluation, adaptations regarding documentation requirements, additional data import requirements (e.g. laboratory systems), and staff trainings
- Potential risks to data integrity, quality including data confidentiality and protection
Implement an amendment:
- In collaboration with the DMan
- Only once EC/RA approval has been received
- Establish and save the database as a new updated version
- Validate the amended database and ensure it works as intended
- Train staff on applicable changes
- Upon successful validation release the updated database for data entry
An amendment might also include the addition of additional study site(s). In that case applicable access rights will have to be updated.
Except for safety amendments aimed at protecting study participants, initiating a protocol amendment should be carefully evaluated as:
- Delays in study conduct are expected. Especially in the event of a substantial amendment, where EC requires 30 days deliberation for mono- and 45 days for multi-centre studies
- The quality of study data might be jeopardised, as the study might end up operating with two or more different and partly incompatible databases. This can lead to challenges during the statistical evaluation of the study
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Clinical Trials Unit, CTU, dkf.unibas.ch
Bellinzona, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.ctc.usz.ch
Swissethics – see in particular
- Amendments – Definition of substantial and non-substantial amendments
ICH GCP E6(R2) – see in particular guidelines
- 5.5. Trial Management, data handling, and record-keeping